High performance liquid chromatography of carbon-11 labeled thymidine and its major catabolites for clinical PET studies.
The identity and pharmacology of the rapidly formed radiolabeled metabolites formed following i.v. injection of C-11 thymidine (TdR) labeled in the 5-methyl-position are being studied in animal models and patients with cancer. A high performance liquid chromatographic (HPLC) procedure has been developed for the separation of these metabolites including thymine, dihydrothymine, beta-ureidoisobutyric acid, and beta-aminoisobutyric acid from plasma and tissue extracts. Information obtained regarding the pharmacokinetics of the metabolites are being used to generate mathematical models for C-11 TdR incorporation rates into DNA.
Conti
P S
PS
Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA.
Hilton
J
J
Wong
D F
DF
Alauddin
M M
MM
Dannals
R F
RF
Ravert
H T
HT
Wilson
A A
AA
Anderson
J H
JH
D000818:Animals; D001932:Brain Neoplasms / Q000097:blood / Q000000981:diagnostic imaging; D002250:Carbon Radioisotopes / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D005909:Glioblastoma / Q000097:blood / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D013936:Thymidine / Q000097:blood / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
D002250:Carbon Radioisotopes; D013936:Thymidine